Clinical trial
A Phase 1/2 Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT04939272 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Lead sponsor
- City of Hope Medical Center
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- June 29, 2022
- Completion date
- February 12, 2027
- Enrollment
- 8 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent mantle cell lymphoma, refractory mantle cell lymphoma